This program is expected to rollout in spring 2026
"Medi-Cal Rx Contract Drugs List (CDL) Update: GLP-1 Agonist Coverage Changes Effective January 1, 2026." Wegovy, Zepbound, and Saxenda removed from CDL for weight loss
Tirzepatide, while FDA-approved for weight loss, was not included because the recency of that approval limited the data available for analysis
Oxylipins regulate a broad range of physiological processes, including cell death, tissue repair, coagulation, cell proliferation, vascular permeability, pain, inflammation, immune functions, and blood pressure (55)
The finished molecule, reduced glutathione (GSH) , is now ready to act as the bodys defense system
Emerging research shows that people who develop sustainable habits while on the medication are more likely to prevent weight regain in the long term 11